Diabetes Combination Studies Leave Market Challenges Unresolved
Novo Nordisk and Sanofi's trials were intended to satisfy FDA's combination product rule, but sponsors have not addressed some important clinical questions around use of the basal insulin/GLP-1 agonist products.
You may also be interested in...
US FDA approves Xultophy and Soliqua, both fixed-ratio combinations of a basal insulin and a GLP-1 agonist, on the same day even though Sanofi redeemed a priority review voucher that earned Soliqua an earlier user fee goal date.
FDA request for more information on pen injector forces three-month review extension, offsetting advantage from priority review voucher redemption.
The first BCMA-targeting agent to gain approval in myeloma never became the blockbuster for which GSK had hoped, but Blenrep appears to have set a new standard for speed of voluntary withdrawal of an accelerated approval drug after a confirmatory trial failure.